Status:
COMPLETED
Health Effects of Salmon Fishmeal in Humans
Lead Sponsor:
University of Oslo
Conditions:
Impaired Glucose Tolerance
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Diabetes contributes significantly to the burden of disease in Norway and cardiovascular disease is the main cause of mortality. Both lean and fatty fish are shown to have beneficial health effects. ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Fasting plasma glucose ≥ 5.6 mmol/l or
- Plasma glucose ≥ 6.5 mmol/l 2h after an OGTT or
- HbA1c ≥ 5.8 %
- Exclusion criteria:
- Diabetes (defined as p-glucose ≥ 7.0 mmol/l p-glucose ≥11,1 mmol/l 2h after OGTT or HbA1c ≥ 6.5 %)
- High fish intake (\> 450 gram/week) or fish allergy
- Age-related elevated blood pressure (≥ 70 år: ≥ 180/110 mmHg, \> 40-70: ≥ 170/100 mmHg and ≤ 40 år: ≥ 160/100 mmHg)
- Use of prescription medicines related to diabetes, inflammation, systemic use of corticosteroids.
- Non-stable use of lipid lowering drugs, thyroxine, blood pressure lowering drugs, drugs affecting appetite, dietary supplements (including n-3)
- High intake of protein supplements powder
- Pregnancy
- Planning pregnancy or changes in body weight
Exclusion
Key Trial Info
Start Date :
September 14 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2019
Estimated Enrollment :
88 Patients enrolled
Trial Details
Trial ID
NCT03764423
Start Date
September 14 2018
End Date
November 1 2019
Last Update
September 28 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Oslo
Oslo, Post Box 1046, Blindern, Norway, 0317